Reported Earlier, Iovance To Present Updated Clinical Data For Lifileucel In Combination With Pembrolizumab In Frontline Advanced Melanoma At ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Iovance Biotherapeutics will present updated clinical data for Lifileucel in combination with Pembrolizumab in frontline advanced melanoma at the ASCO Annual Meeting. The data shows promising response rates and durable responses in patients naïve to immune checkpoint inhibitor therapy, supporting the ongoing Phase 3 TILVANCE-301 trial.
May 24, 2024 | 11:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iovance Biotherapeutics will present promising clinical data for Lifileucel in combination with Pembrolizumab in frontline advanced melanoma at the ASCO Annual Meeting. The data shows strong response rates and durable responses, supporting the ongoing Phase 3 TILVANCE-301 trial.
The presentation of promising clinical data at a major conference like ASCO is likely to positively impact Iovance Biotherapeutics' stock price. The strong response rates and durable responses observed in the trial support the ongoing Phase 3 TILVANCE-301 trial, which is a critical milestone for the company.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100